Implications of Covid-19 on Market Access and Pricing

In the longer term, we foresee six areas of impact of Covid-19 on Market Access in the medium- to long-term:

Changes in priorities and funding :

1. Drug budget re-allocation across Therapeutic Areas
2. More focus and funding for prevention and care provision 
3. Accelerated funding and adoption of digital solutions and virtual health

New rules of the game:

1. New criteria for drug assessments
2. More coordination between actors within countries & across countries 
3. More regulation

Given these changing dynamics, it is critical for Market Access and Pricing leaders to anticipate these evolution, including:

• Scan the portfolio to understand and plan for asset-specific implications
• Refresh all payer engagement materials and messaging 
• Re-think pricing and contracting strategy, including developing more innovative financing offers to anticipate budget pressure 
• Design an adapted payer engagement plan, to prepare and adapt to more digital interactions